Abstract
National recommendations for lung cancer screening for former and current smokers aged 55-80 years with a 30-pack year smoking history create demand to implement efficient and effective systems to offer smoking cessation on a large scale. These older, high-risk smokers differ from participants in past clinical trials of behavioral and pharmacologic interventions for tobacco dependence. There is a gap in knowledge about how to best design systems to extend reach and treatments to maximize smoking cessation in the context of lung cancer screening.
Eight clinical trials, seven funded by the National Cancer Institute and one by the VHA, address this gap and form the Smoking Cessation within the Context of Lung Cancer Screening (SCALE) collaboration. This paper describes methodological issues related to the design of these clinical trials: clinical workflow, participant eligibility criteria, screening indication (baseline or annual repeat screen), assessment content, interest in stopping smoking, and treatment delivery method and dose, all of which will affect tobacco treatment outcomes.
Tobacco interventions consider the “teachable moment” offered by lung cancer screening, how to incorporate positive and negative screening results, and coordination of smoking cessation treatment with clinical events associated with lung cancer screening. Unique data elements, such as perceived risk of lung cancer and costs of tobacco treatment are of interest. Lung cancer screening presents a new and promising opportunity to reduce morbidity and mortality from lung cancer that can be amplified by effective smoking cessation treatment. SCALE teamwork and collaboration promises to maximize knowledge gained from the clinical trials.
